STIM VS JNJ Stock Comparison
Performance
STIM10/100
10/100
STIM returned -72.04% in the last 12 months. Based on SPY's performance of -13.39%, its performance is below average giving it a score of 10 of 100.
JNJ73/100
73/100
JNJ returned -15.84% in the last 12 months. Based on SPY's performance of -20.60%, its performance is above average giving it a score of 73 of 100.
Analyst Price Targets
STIM90/100
90/100
5 analysts offer 12-month price targets for STIM. Together, they have an average target of 8, the most optimistic target put STIM at 8 within 12-months and the most pessimistic has STIM at 8.
JNJ63/100
63/100
23 analysts offer 12-month price targets for JNJ. Together, they have an average target of 176.5, the most optimistic target put JNJ at 205 within 12-months and the most pessimistic has JNJ at 90.
Sentiment
STIM74/100
74/100
STIM had a bullish sentiment score of 74.22% across Twitter and StockTwits over the last 12 months. It had an average of 3.11 posts, 0.22 comments, and 0.44 likes per day.
JNJ72/100
72/100
JNJ had a bullish sentiment score of 71.87% across Twitter and StockTwits over the last 12 months. It had an average of 205.31 posts, 3,341.61 comments, and 16,552.61 likes per day.
Technicals
STIM64/100
64/100
STIM receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.
JNJ14/100
14/100
JNJ receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.
Earnings
STIM24/100
24/100
STIM has missed earnings 4 times in the last 20 quarters.
JNJ100/100
100/100
JNJ has missed earnings 0 times in the last 20 quarters.
Profit
STIM10/100
10/100
Out of the last 20 quarters, STIM has had 0 profitable quarters and has increased their profits year over year on 0 of them.
JNJ74/100
74/100
Out of the last 20 quarters, JNJ has had 19 profitable quarters and has increased their profits year over year on 9 of them.
Volatility
STIM33/100
33/100
STIM has had a lower than average amount of volatility over the last 12 months giving it a score of 33 of 100.
JNJ43/100
43/100
JNJ has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.
Dividend
STIM
"Dividend" not found for STIM
JNJ100/100
100/100
JNJ's most recent dividend was $0.90 per share, based on a share price of $145.60. It was a payout ratio of 61.39% compared to their total earnings.
All score calculations are broken down here to help you make more informed investing decisions
Neuronetics, Inc. Common Stock Summary
Nasdaq / STIM
Healthcare
Medical - Diagnostics & Research
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Johnson & Johnson Summary
New York Stock Exchange / JNJ
Healthcare
Drug Manufacturers - General
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare STIM to other companies in the same or a similar industry.